Research ExplorerPublicationsHolmium laser enucleation of the prostate is safe in patient...

Holmium laser enucleation of the prostate is safe in patients with prostate cancer and lower urinary tract symptoms--a retrospective feasibility study

Standard

Holmium laser enucleation of the prostate is safe in patients with prostate cancer and lower urinary tract symptoms--a retrospective feasibility study. / Becker, Andreas; Placke, Anne ; Kluth, Luis; Schwarz, Rudolf; Isbarn, Hendrik; Chun, Felix; Heuer, Roman; Schlomm, Thorsten; Seiler, Daniel; Engel, Oliver; Fisch, Margit; Graefen, Markus; Ahyai, Sascha A.

In: J ENDOUROL, Vol. 28, No. 3, 01.03.2014, p. 335-41.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Becker, A, Placke, A, Kluth, L, Schwarz, R, Isbarn, H, Chun, F, Heuer, R, Schlomm, T, Seiler, D, Engel, O, Fisch, M, Graefen, M & Ahyai, SA 2014, 'Holmium laser enucleation of the prostate is safe in patients with prostate cancer and lower urinary tract symptoms--a retrospective feasibility study', J ENDOUROL, vol. 28, no. 3, pp. 335-41. https://doi.org/10.1089/end.2013.0432

APA

Becker, A., Placke, A., Kluth, L., Schwarz, R., Isbarn, H., Chun, F., Heuer, R., Schlomm, T., Seiler, D., Engel, O., Fisch, M., Graefen, M., & Ahyai, S. A. (2014). Holmium laser enucleation of the prostate is safe in patients with prostate cancer and lower urinary tract symptoms--a retrospective feasibility study. J ENDOUROL, 28(3), 335-41. https://doi.org/10.1089/end.2013.0432

Vancouver

Becker A, Placke A, Kluth L, Schwarz R, Isbarn H, Chun F et al. Holmium laser enucleation of the prostate is safe in patients with prostate cancer and lower urinary tract symptoms--a retrospective feasibility study. J ENDOUROL. 2014 Mar 1;28(3):335-41. https://doi.org/10.1089/end.2013.0432

Bibtex

@article{668495afd6884f9eb6a70574633d28c0,
title = "Holmium laser enucleation of the prostate is safe in patients with prostate cancer and lower urinary tract symptoms--a retrospective feasibility study",
abstract = "OBJECTIVE: To evaluate the outcome of holmium laser enucleation of the prostate (HoLEP) in the known presence of prostate cancer (PCa) and concomitant lower urinary tract symptoms (LUTS).PATIENTS AND METHODS: We retrospectively identified 62 patients who underwent HoLEP for LUTS in the known presence of PCa at our center. Perioperative data were assessed including complications, functional outcomes, and quality of life (QoL). Giving respect to different disease characteristics, patients were stratified according to treatment strategy setting into palliative (I), radiation (II), and surveillance (III) groups and compared accordingly.RESULTS: Median follow-up (FU) of the entire study cohort was 27 months (range 2-65 mos). Medians of functional parameters (International Prostate Symptom Score): 18.5 vs 4.5, QoL: 4 vs 1, maximal flow rate: 9.0 vs 18.8 mL/s and residual urine: 100 vs 0 mL, all P<0.05) improved significantly in all groups. Perioperative complications were low and without any statistically significant difference between the groups. Postoperatively, voiding was successful in 90.3% of all patients; at last FU, 17% had some degree of urinary incontinence. Treatment strategy groups showed comparable functional outcomes after HoLEP.CONCLUSION: In the presence of PCa and LUTS, HoLEP represents a feasible, safe, and effective treatment option for patients unfit or without indication for radical prostatectomy. This applies as well in a palliative situation of advanced, obstructive PCa as for patients with LUTS who are scheduled for radiation therapy or surveillance in presumably indolent disease.",
keywords = "Aged, Aged, 80 and over, Feasibility Studies, Follow-Up Studies, Humans, Laser Therapy, Lasers, Solid-State, Lower Urinary Tract Symptoms, Male, Middle Aged, Prostatectomy, Prostatic Neoplasms, Quality of Life, Retrospective Studies, Treatment Outcome, Urination",
author = "Andreas Becker and Anne Placke and Luis Kluth and Rudolf Schwarz and Hendrik Isbarn and Felix Chun and Roman Heuer and Thorsten Schlomm and Daniel Seiler and Oliver Engel and Margit Fisch and Markus Graefen and Ahyai, {Sascha A}",
year = "2014",
month = mar,
day = "1",
doi = "10.1089/end.2013.0432",
language = "English",
volume = "28",
pages = "335--41",
journal = "J ENDOUROL",
issn = "0892-7790",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

RIS

TY - JOUR

T1 - Holmium laser enucleation of the prostate is safe in patients with prostate cancer and lower urinary tract symptoms--a retrospective feasibility study

AU - Becker, Andreas

AU - Placke, Anne

AU - Kluth, Luis

AU - Schwarz, Rudolf

AU - Isbarn, Hendrik

AU - Chun, Felix

AU - Heuer, Roman

AU - Schlomm, Thorsten

AU - Seiler, Daniel

AU - Engel, Oliver

AU - Fisch, Margit

AU - Graefen, Markus

AU - Ahyai, Sascha A

PY - 2014/3/1

Y1 - 2014/3/1

N2 - OBJECTIVE: To evaluate the outcome of holmium laser enucleation of the prostate (HoLEP) in the known presence of prostate cancer (PCa) and concomitant lower urinary tract symptoms (LUTS).PATIENTS AND METHODS: We retrospectively identified 62 patients who underwent HoLEP for LUTS in the known presence of PCa at our center. Perioperative data were assessed including complications, functional outcomes, and quality of life (QoL). Giving respect to different disease characteristics, patients were stratified according to treatment strategy setting into palliative (I), radiation (II), and surveillance (III) groups and compared accordingly.RESULTS: Median follow-up (FU) of the entire study cohort was 27 months (range 2-65 mos). Medians of functional parameters (International Prostate Symptom Score): 18.5 vs 4.5, QoL: 4 vs 1, maximal flow rate: 9.0 vs 18.8 mL/s and residual urine: 100 vs 0 mL, all P<0.05) improved significantly in all groups. Perioperative complications were low and without any statistically significant difference between the groups. Postoperatively, voiding was successful in 90.3% of all patients; at last FU, 17% had some degree of urinary incontinence. Treatment strategy groups showed comparable functional outcomes after HoLEP.CONCLUSION: In the presence of PCa and LUTS, HoLEP represents a feasible, safe, and effective treatment option for patients unfit or without indication for radical prostatectomy. This applies as well in a palliative situation of advanced, obstructive PCa as for patients with LUTS who are scheduled for radiation therapy or surveillance in presumably indolent disease.

AB - OBJECTIVE: To evaluate the outcome of holmium laser enucleation of the prostate (HoLEP) in the known presence of prostate cancer (PCa) and concomitant lower urinary tract symptoms (LUTS).PATIENTS AND METHODS: We retrospectively identified 62 patients who underwent HoLEP for LUTS in the known presence of PCa at our center. Perioperative data were assessed including complications, functional outcomes, and quality of life (QoL). Giving respect to different disease characteristics, patients were stratified according to treatment strategy setting into palliative (I), radiation (II), and surveillance (III) groups and compared accordingly.RESULTS: Median follow-up (FU) of the entire study cohort was 27 months (range 2-65 mos). Medians of functional parameters (International Prostate Symptom Score): 18.5 vs 4.5, QoL: 4 vs 1, maximal flow rate: 9.0 vs 18.8 mL/s and residual urine: 100 vs 0 mL, all P<0.05) improved significantly in all groups. Perioperative complications were low and without any statistically significant difference between the groups. Postoperatively, voiding was successful in 90.3% of all patients; at last FU, 17% had some degree of urinary incontinence. Treatment strategy groups showed comparable functional outcomes after HoLEP.CONCLUSION: In the presence of PCa and LUTS, HoLEP represents a feasible, safe, and effective treatment option for patients unfit or without indication for radical prostatectomy. This applies as well in a palliative situation of advanced, obstructive PCa as for patients with LUTS who are scheduled for radiation therapy or surveillance in presumably indolent disease.

KW - Aged

KW - Aged, 80 and over

KW - Feasibility Studies

KW - Follow-Up Studies

KW - Humans

KW - Laser Therapy

KW - Lasers, Solid-State

KW - Lower Urinary Tract Symptoms

KW - Male

KW - Middle Aged

KW - Prostatectomy

KW - Prostatic Neoplasms

KW - Quality of Life

KW - Retrospective Studies

KW - Treatment Outcome

KW - Urination

U2 - 10.1089/end.2013.0432

DO - 10.1089/end.2013.0432

M3 - SCORING: Journal article

C2 - 24147796

VL - 28

SP - 335

EP - 341

JO - J ENDOUROL

JF - J ENDOUROL

SN - 0892-7790

IS - 3

ER -